Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29581086 | 0.75 | ALDH1A1 (0.58) | ALDH1A1MAPTGAALMNAKMT2A | |
| SCHEMBL10094604 | 0.75 | ALDH1A1 (0.58) | ALDH1A1MAPTGAALMNARAB9A | |
| SCHEMBL13887212 | 0.74 | SMN1; SMN2 (0.47) | ALDH1A1MAPTGAALMNAKMT2A | |
| SCHEMBL10094181 | 0.71 | ALDH1A1 (0.53) | ALDH1A1MAPTGAALMNARAB9A | |
| SCHEMBL1319274 | 0.69 | ALDH1A1 (1.00) | ALDH1A1MAPTGAALMNAKMT2A | |
| SCHEMBL4159994 | 0.69 | MEN1 (0.52) | ALDH1A1MAPTLMNAKMT2AMEN1 | |
| SCHEMBL14850496 | 0.69 | ALDH1A1 (0.55) | ALDH1A1MAPTGAALMNAKMT2A | |
| SCHEMBL21463918 | 0.69 | MAPK1 (0.53) | ALDH1A1MAPTGAALMNAKMT2A | |
| SCHEMBL30615434 | 0.69 | MAPK1 (0.53) | ALDH1A1MAPTGAALMNAKMT2A | |
| SCHEMBL3595694 | 0.68 | ALDH1A1 (0.68) | ALDH1A1MAPTGAAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514445-B2 | Heteroaryl amines as glycogen synthase kinase 3β inhibitors (GSK3 inhibitors) | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-07 | — | — | US | disclosed |
| US-20050004125-A1 | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-06 | — | — | US | disclosed |
| EP-1448556-A1 | HETEROARYL AMINES AS GLYCOGEN SYNTHASE KINASE 3BETA INHIBITORS (GSK3 INHIBITORS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003037891-A1 | HETEROARYL AMINES AS GLYCOGEN SYNTHASE KINASE 3BETA INHIBITORS (GSK3 INHIBITORS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004125-A1 | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) | GSK3B, GSK3A, GSKIP | ALDH1A1 3842/4885MAPT 1460/4885GAA 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.